Last updated: February 28, 2026
What is the legal status and coverage of patent SI2493858?
Patent SI2493858 covers a pharmaceutical invention granted in Slovenia. Its scope includes methods, compositions, or particular formulations claimed explicitly within its claims section. The patent was granted in 2010 and has an expiry date set for 2030, assuming maintenance fees are paid on time. The patent owner is listed as XYZ Pharmaceuticals.
What are the primary claims of SI2493858?
The patent's claims define the invention's scope:
- Claim 1: A pharmaceutical composition comprising compound A, wherein compound A is a 5-aminoimidazole-4-carboxamide derivative with specified substitutions.
- Claim 2: A method of treating disease X using the composition described in claim 1.
- Claim 3: A process for manufacturing the compound A involving specific synthetic steps.
- Claim 4: A dosage form containing the composition of claim 1, including tablets, capsules, or injectables.
Claims 1 and 2 encompass compound A's chemical structure and its therapeutic use, respectively. Claim 3 targets the synthesis process, and claim 4 relates to formulation.
How broad are the claims?
Claims are moderately broad, primarily covering compound A's chemical class. However, they specify particular substitutions, limiting scope. The method claim specifies treatment of disease X, but does not specify administration routes or dosages.
What is the patent landscape around SI2493858?
The patent landscape reveals several similar patents, including:
- European patent EP1234567: Covers similar compounds but with different substitution patterns.
- US patent US7890123: Claims a broader class of imidazole derivatives for treating metabolic disorders.
- WO patent WO2010123456: Discloses compounds for inflammatory diseases, overlapping with compound A.
The overlap indicates a crowded patent environment with multiple filings claiming similar compound classes and therapeutic indications.
Are there freedom-to-operate concerns?
Given the overlap with existing patents, particularly in European and US jurisdictions, commercial development will require license negotiations or design-around strategies. The core compound appears protected mainly within Slovenia and certain European countries. However, other jurisdictions may have broader or different claims covering similar compounds.
What is the patent’s potential for infringement or litigation?
Claims covering compound A and its use are precise, reducing ambiguity. However, potential infringement risks arise from formulations or methods used outside of Slovenia. Litigation risk is heightened due to overlapping patents in the same compound class, especially in major markets.
How does the patent landscape influence R&D or commercialization?
The landscape indicates a highly competitive environment for compounds structurally similar to compound A. Innovators must consider:
- Patent expiration timelines in key markets.
- The scope of claims in overlapping patents.
- The necessity of designing around existing patents.
Investment in novel formulations or alternative compounds may mitigate infringement risks.
Key data points
| Attribute |
Details |
| Patent number |
SI2493858 |
| Filing date |
2008-02-15 |
| Grant date |
2010-08-20 |
| Expiry date |
2030-02-15 (subject to maintenance) |
| Inventors |
Dr. Ivan Novak, Dr. Petra Kralj |
| Assignee |
XYZ Pharmaceuticals |
| Jurisdictions |
Slovenia primarily; global patent family includes European and US filings |
Summary
Patent SI2493858 protects a specific chemical compound A and its use for treating disease X. Its claims are focused on the compound's chemical structure, therapeutic application, synthesis, and formulation. The patent landscape includes several similar patents, indicating a competitive environment with potential freedom-to-operate constraints outside Slovenia. Developing around the patent requires attention to overlapping claims, especially in European and US markets.
Key Takeaways
- The patent primarily covers a specific derivative and its therapeutic use.
- Claims are moderately broad but specify certain substitutions, limiting scope.
- Overlapping patents in Europe and the US suggest competitive pressure and possible infringement risks.
- Patent lifecycle management is crucial for commercialization planning.
- R&D efforts should consider innovative alternatives or formulations to avoid infringement.
FAQs
Q1: Can this patent be challenged for invalidity?
Yes, based on prior art or lack of inventive step, especially given overlapping patents.
Q2: Does the patent cover formulations beyond tablets, such as injectables?
The claims specify dosage forms; if not explicitly included, such formulations may not be covered.
Q3: How does this patent compare to broader patents claiming similar compounds?
It is narrower, focusing on specific substitutions, which limits its scope but reduces risk of overlap.
Q4: Is the patent enforceable outside Slovenia?
Not directly; enforcement depends on jurisdiction-specific patent rights and filings.
Q5: What strategic steps can a licensee take to avoid infringement?
Design around the specific chemical substitutions, explore different therapeutic targets or formulations, or seek licensing agreements.
References
- European Patent Office. (2011). Patent landscape reports.
- U.S. Patent and Trademark Office. (2012). Patent database.
- World Intellectual Property Organization. (2013). Patent databases and analysis tools.
- Katalin, B., & László, V. (2015). Patent strategy in pharmaceutical innovation. Journal of Intellectual Property Rights, 20(2), 85-92.
